<?xml version='1.0' encoding='utf-8'?>
<document id="22212583"><sentence text="Hepatitis C virus-human immunodeficiency virus coinfection." /><sentence text="As a result of shared modes of transmission, chronic hepatitis C infection is common in HIV-infected patients, particularly among those who have used injection drugs as well as men who have sex with men (MSMs)" /><sentence text=" In the era of effective antiretroviral therapy, HCV infection has emerged as a major cause of morbidity and mortality worldwide" /><sentence text=" Over the last decade, treatment with peginterferon (PEG-IFN) plus ribavirin (RBV) has been recommended for coinfected patients who are at the greatest risk for liver disease; however, the effectiveness of HCV treatment in this population has been disappointing"><entity charOffset="67-76" id="DDI-PubMed.22212583.s4.e0" text="ribavirin" /><entity charOffset="78-81" id="DDI-PubMed.22212583.s4.e1" text="RBV" /><pair ddi="false" e1="DDI-PubMed.22212583.s4.e0" e2="DDI-PubMed.22212583.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22212583.s4.e0" e2="DDI-PubMed.22212583.s4.e1" /></sentence><sentence text=" Challenges to the use of HCV NS3/4A protease inhibitors, telaprevir and boceprevir, patients with HIV/HCV coinfection include the potential for interactions between different drugs, addition of drug toxicities, and the need for therapy with PEG-IFN"><entity charOffset="58-68" id="DDI-PubMed.22212583.s5.e0" text="telaprevir" /><entity charOffset="73-83" id="DDI-PubMed.22212583.s5.e1" text="boceprevir" /><pair ddi="false" e1="DDI-PubMed.22212583.s5.e0" e2="DDI-PubMed.22212583.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22212583.s5.e0" e2="DDI-PubMed.22212583.s5.e1" /></sentence><sentence text=" Despite these challenges, limited data indicate that telaprevir and boceprevir given in combination with PEG-IFN/RBV increase the rate of viral suppression in coinfected patients with manageable toxicity and drug-drug interaction profile"><entity charOffset="54-64" id="DDI-PubMed.22212583.s6.e0" text="telaprevir" /><entity charOffset="69-79" id="DDI-PubMed.22212583.s6.e1" text="boceprevir" /><entity charOffset="114-123" id="DDI-PubMed.22212583.s6.e2" text="RBV" /><pair ddi="false" e1="DDI-PubMed.22212583.s6.e0" e2="DDI-PubMed.22212583.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22212583.s6.e0" e2="DDI-PubMed.22212583.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22212583.s6.e0" e2="DDI-PubMed.22212583.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22212583.s6.e1" e2="DDI-PubMed.22212583.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22212583.s6.e1" e2="DDI-PubMed.22212583.s6.e2" /></sentence><sentence text=" Accordingly, these agents may be recommended for HCV treatment in carefully selected HIV-infected persons" /><sentence text="" /></document>